ReNeuron Group PLC (LSE:RENE) - Share price


Stock Report

ReNeuron Group PLC RENE

Last Price
GBX170.50

Day Change
10.50|6.56%

As of 22/01/2020
16:13:21 GMT | GBX
Minimum 15 Minutes Delay.

Last Close160.00p
Day Range160.05 - 178.00
Mkt Cap50.93Mil
52-Wk Range29.50 - 342.00
Yield %-
ISINGB00BF5G6K95
Volume244,098
P/E-
P/S11.00
P/CF-0.04

Share Price

Total Returns 21/01/2020

 Chg (%)  
More ...
ReNeuron Group PLC23.08 
FTSE 100 TR GBP-0.01
 
Financials
201720182019
More ...
Income Statement
Turnover0.050.040.05
Operating Profit-19.89-20.38-18.28
Net Profit-15.57-17.62-14.29
Reported EPS-49.20-55.70-45.20
Balance Sheet
Current Assets58.1441.7130.03
Non Current Assets0.720.910.82
Total Assets58.8642.6230.85
Current Liabilities5.705.957.43
Total Liabilities---
Total Equity53.1636.6723.42
Cash Flow
Operating Cash Flow-13.98-19.24-15.12
Net Change in Cash10.70-0.21-7.48

Regulatory News

DateAuthor Headline
24/11/2014Emma Wall Woodford to Launch Second Fund
Six months after the successful launch of his equity income fund, veteren investor Neil Woodford is considering a global smaller companies fund 
14/07/2014Emma Wall Woodford's Full Portfolio Revealed
Woodford is maximising his overseas exposure and allocating a third of the portfolio to his favourite sector, pharmaceuticals, as well as a surprisingly high financials exposure
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
18/04/2019PurchaseSir Christopher Thomas Evans OBE228.7010,00022,870.00
12/04/2019Sale of OptionMichael Elliott Hunt247.009882,440.00
12/04/2019Exercise of OptionMichael Elliott Hunt100.003,4783,478.00
11/04/2019PurchaseMr. John E. Berriman225.0080,000180,000.00

Company Profile

ReNeuron Group PLC is a biotechnology firm. Its principal business involves the research and development of stem cell technology for the treatment of motor disabilities and blindness-causing diseases.

Sector

Biotechnology

Index

FTSE AIM All-Share

Next Event 10/07/2020

Final Results
Ratios
Comp
More ...
PER (E)0.00
Div Yld (E)0.00
PEG (E)0.00
ROCE-78.07
Op Mrgn-373.10
EPS Grwth0.00
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
Directors
More ...
Non-Executive Director, ChairmanMr. John E. Berriman
Non-Executive DirectorSir Christopher Thomas Evans OBE
Non-Executive DirectorSimon C Cartmell
Executive Director, Chief Financial Officer and Company SecretaryMichael Elliott Hunt
Non-Executive DirectorDr. Tim Corn
Executive Director, Chief Executive OfficerMr. Olav Hellebo
Non-Executive DirectorDr. Michael John Owen
Non-Executive DirectorDr. Claudia D'Augusta
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2020 Morningstar. All rights reserved.